

P&T Motion History
Diabetes Drugs – DPP-4 Inhibitors

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
alogliptin alogliptin + metformin alogliptin + pioglitazone linagliptin linagliptin + metformin linagliptin + metformin ER saxagliptin saxagliptin + metformin ER sitagliptin sitagliptin + metformin sitagliptin XR + metformin	After considering the evidence of safety, efficacy and special populations for the treatment of diabetes, I move that DPP-4 inhibitors linagliptin, saxagliptin, alogliptin, sitagliptin and all listed combination drugs in this sub-class are safe and efficacious. DPP-4 inhibitors can be subject to therapeutic interchange in the Washington preferred drug list. Therapeutic interchange is allowed only within each diabetes sub-class. Motion: Figueroa 2 nd : Lee	December 19, 2018	Yes Flatebo Sanderson	Yes Figueroa Park	Passed unanimous
		October 18, 2017	NA	No	Passed unanimous